ES2300639T3 - Derivados de piridino-2,3-dipirimidina como inhibidores selectivos de kdr y fgfr. - Google Patents

Derivados de piridino-2,3-dipirimidina como inhibidores selectivos de kdr y fgfr. Download PDF

Info

Publication number
ES2300639T3
ES2300639T3 ES03785789T ES03785789T ES2300639T3 ES 2300639 T3 ES2300639 T3 ES 2300639T3 ES 03785789 T ES03785789 T ES 03785789T ES 03785789 T ES03785789 T ES 03785789T ES 2300639 T3 ES2300639 T3 ES 2300639T3
Authority
ES
Spain
Prior art keywords
alkyl
phenyl
pyrimidin
substituted
propionic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03785789T
Other languages
English (en)
Spanish (es)
Inventor
Jin-Jun Liu
Kin-Chun Luk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2300639T3 publication Critical patent/ES2300639T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES03785789T 2002-12-20 2003-12-11 Derivados de piridino-2,3-dipirimidina como inhibidores selectivos de kdr y fgfr. Expired - Lifetime ES2300639T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43496902P 2002-12-20 2002-12-20
US434969P 2002-12-20
US51361503P 2003-10-23 2003-10-23
US513615P 2003-10-23

Publications (1)

Publication Number Publication Date
ES2300639T3 true ES2300639T3 (es) 2008-06-16

Family

ID=32685355

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03785789T Expired - Lifetime ES2300639T3 (es) 2002-12-20 2003-12-11 Derivados de piridino-2,3-dipirimidina como inhibidores selectivos de kdr y fgfr.

Country Status (15)

Country Link
US (1) US7098332B2 (https=)
EP (1) EP1581531B1 (https=)
JP (1) JP2006511563A (https=)
KR (1) KR100763298B1 (https=)
AR (1) AR042532A1 (https=)
AT (1) ATE387445T1 (https=)
AU (1) AU2003294830B2 (https=)
BR (1) BR0317480A (https=)
CA (1) CA2508951A1 (https=)
DE (1) DE60319430T2 (https=)
ES (1) ES2300639T3 (https=)
MX (1) MXPA05006437A (https=)
PL (1) PL377661A1 (https=)
RU (1) RU2345077C2 (https=)
WO (1) WO2004056822A1 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) * 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
BRPI0413018B8 (pt) * 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
ATE373659T1 (de) * 2004-05-04 2007-10-15 Warner Lambert Co Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel
EP1814878B1 (en) * 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
US20090312321A1 (en) * 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
DK2074122T5 (da) * 2006-09-15 2014-03-17 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
CN105683188B (zh) * 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
MA38393B1 (fr) * 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
MX373150B (es) 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
JP6585167B2 (ja) * 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2887148T3 (es) 2015-03-25 2021-12-21 Nat Cancer Ct Agente terapéutico contra el cáncer de vías biliares
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US12414945B2 (en) 2015-12-17 2025-09-16 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
AU2018229148B2 (en) * 2017-03-03 2022-08-04 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN110914267B (zh) * 2017-07-19 2022-07-12 江苏奥赛康药业有限公司 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用
SG11202007591RA (en) 2018-03-28 2020-09-29 Eisai R&D Man Co Ltd Therapeutic agent for hepatocellular carcinoma
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
MA54608B1 (fr) 2018-12-27 2023-02-28 Servier Lab Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
AR119046A1 (es) * 2019-05-31 2021-11-17 Agios Pharmaceuticals Inc Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112062770A (zh) * 2020-08-21 2020-12-11 台州学院 一种稠环二氢吡啶酮的制备方法
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76853A (en) * 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
NZ510760A (en) 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles
DE60006503T2 (de) 1999-03-16 2004-09-23 Shell Internationale Research Maatschappij B.V. Verfahren zur reinigung von propylenoxid
MY141144A (en) 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CA2417942C (en) 2000-08-04 2010-06-29 Warner-Lambert Company 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
US6960662B2 (en) 2000-08-04 2005-11-01 Warner-Lambert Company Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
WO2002018380A1 (en) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
DE60239097D1 (de) * 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem

Also Published As

Publication number Publication date
RU2005122901A (ru) 2006-02-27
KR100763298B1 (ko) 2007-10-04
EP1581531A1 (en) 2005-10-05
MXPA05006437A (es) 2005-08-19
WO2004056822A1 (en) 2004-07-08
PL377661A1 (pl) 2006-02-06
ATE387445T1 (de) 2008-03-15
US7098332B2 (en) 2006-08-29
KR20050088202A (ko) 2005-09-02
AU2003294830A1 (en) 2004-07-14
US20040122029A1 (en) 2004-06-24
JP2006511563A (ja) 2006-04-06
AR042532A1 (es) 2005-06-22
BR0317480A (pt) 2005-11-16
EP1581531B1 (en) 2008-02-27
DE60319430D1 (de) 2008-04-10
RU2345077C2 (ru) 2009-01-27
AU2003294830B2 (en) 2009-06-11
DE60319430T2 (de) 2009-02-26
CA2508951A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
ES2300639T3 (es) Derivados de piridino-2,3-dipirimidina como inhibidores selectivos de kdr y fgfr.
ES2300644T3 (es) Compuestos pirimido con actividad antiproliferativa.
ES2298622T3 (es) Derivados de pirimido 4,5-d-pirimidina con actividad anticancerigena.
JP2022537876A (ja) カゼインキナーゼ１ε阻害剤、医薬組成物及びその使用
JP2009525292A (ja) ７ｈ−ピリド［３，４−ｄ］ピリミジン−８−オン、それらの製造及びプロテインキナーゼ阻害剤としての使用
CN100420687C (zh) 作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物
JP2012524751A (ja) 癌の治療用ｐｉ３−キナーゼ阻害薬としてのチア−トリアザ−シクロペンタアズレン
KR20050042147A (ko) 항증식 활성을 갖는 피리미도 화합물